Abstract:Abstract Objective Contribution of individual and combined inflammatory markers in prognosis after stroke was still undefined. We aimed to investigate the association of systemic and local vascular inflammatory markers and recurrent stroke as well as impact on poor functional outcome. Methods In this pre-specified substudy of the Third China National Stroke Registry (CNSR-III), 10,472 consecutive acute ischemic stroke or TIA patients with available centralized-measured levels of Interleukin-6 (IL-6), high sensitive C-reactive protein (hsCRP), IL-1 receptor antagonist (IL-1Ra), lipoprotein-associated phospholipase A 2 mass (Lp-PLA 2 ) and activity (Lp-PLA 2 -A), and YKL-40 from 171 sites were enrolled. The primary outcomes consisted of stroke recurrence and poor functional outcome defined as modified Rankin Scale (mRS) score of 2–6 within 1 year. Results There were 1026 (9.8%) and 2395 (23.4%) patients with recurrent stroke and poor functional outcome within 1 year. The highest quartiles of IL-6 (adjusted HR, 1.36; 95% CI 1.13–1.64; P = 0.001), hsCRP (adjusted HR, 1.41; 95% CI 1.17–1.69; P = 0.0003) and YKL-40 (adjusted HR, 1.28; 95% CI 1.06–1.56; P = 0.01) were associated with increased risk of recurrent stroke; and the highest quartiles of IL-6 (adjusted OR 1.93; 95% CI 1.64–2.27; P < 0.0001), IL-1Ra (adjusted OR 1.60; 95% CI 1.37–1.87; P < 0.0001), hsCRP (adjusted OR 1.60; 95% CI 1.37–1.86; P < 0.0001) and YKL-40 (adjusted OR 1.21; 95% CI 1.03–1.42; P = 0.02) were correlated with increased risk of poor functional outcome. In the multivariate stepwise regression analysis including all markers with backward selection, elevated levels of IL-6 or YKL-40 were associated with recurrent stroke (IL6: OR, 1.34; 95% CI 1.19–1.52; P < 0.0001; YKL-40: OR, 1.01; 95% CI 1.01–1.03; P = 0.004) and poor functional outcome (IL6: OR, 1.68; 95% CI 1.46–1.93; P < 0.0001; YKL-40: OR, 1.02; 95% CI 1.01–1.03; P = 0.0001). Adding IL-6 and YKL-40 significantly increased the area under the receiver operating characteristic curves for the prediction models of Essen Stroke Risk Score (0.03, P < 0.0001) and Totaled Health Risks in Vascular Events Score (0.07, P < 0.0001), and yielded continuous net reclassification improvement (19.0%, P < 0.0001; 33.0, P < 0.0001). Conclusions In the patients with ischemic stroke or TIA, IL-6 and YKL-40 were independently associated with recurrent stroke and poor functional outcome, and improved risk classification of clinical risk algorithms.

Increased interleukin-18 level contributes to the development and severity of ischemic stroke

Interleukin 8 (CXCL8)-CXC chemokine receptor 2 (CXCR2) axis contributes to MiR-4437-associated recruitment of granulocytes and natural killer cells in ischemic stroke.

Relationship Between Serum Concentrations of IL-18, IL-10, IL-6 and Acute Coronary Syndrome

Clinical significance of serum interleukin-18 (IL-18) and matrix metalloproteinase-(MMP-9) on acute coronary syndrome

Interleukin-18 promoter polymorphisms and risk of ischemic stroke

Increased serum interleukin-34 levels as a novel diagnostic and prognostic biomarker in patients with acute ischemic stroke

Association between interleukin-6 levels and stroke: a systematic review and meta-analysis

Prognostic significance of IL‐18 in acute coronary syndrome patients

Association of Interleukin-1 Gene Cluster Polymorphisms with Ischemic Stroke in A Chinese Population

Interleukin-18 Gene Promoter 607A Polymorphism, but Not 137C Polymorphism, is a Protective Factor for Ischemic Stroke in the Chinese Population: A Meta-Analysis.

Interleukin-6 and YKL-40 predicted recurrent stroke after ischemic stroke or TIA: analysis of 6 inflammation biomarkers in a prospective cohort study

Association of Incident Stroke Risk With an IL-18-Centered Inflammatory Network Biomarker Composite

Novel inflammatory biomarkers associated with stroke severity: results from a cross-sectional stroke cohort study

Inflammatory markers as independent predictors for stroke outcomes

Plasma Interleukin-37 is Elevated in Acute Ischemic Stroke Patients and Probably Associated With 3-month Functional Prognosis

Interleukin-18 Levels on Admission Are Associated with Mid-Term Adverse Clinical Events in Patients with ST-Segment Elevation Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention

Relationship of Serum Interleukin-10 and Its Genetic Variations with Ischemic Stroke in a Chinese General Population.

Relationship between Serum Inflammatory Biomarkers and Ischemic Cerebrovascular Diseases

IL-6 and stroke recurrence in ischemic stroke

The Contribution of Inflammation to Stroke Recurrence Attenuates at Low LDL-C Levels

Inflammatory marker profiles and in‐hospital neurological deterioration in patients with acute minor ischemic stroke